Idorsia’s Phase 3 analysis showed daridorexant 50 mg improved wake-after-sleep-onset by ~43 minutes, sleep latency by ~34 minutes and total sleep time by ~75 minutes versus placebo in menopausal-aged women with insomnia. Health Canada approved JERAYGO for resistant hypertension, authorizing a 12.5 mg dose titratable to 25 mg for enhanced blood pressure control.